Last updated on December 2019

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive HER2 Negative Metastatic Breast Cancer

Brief description of study

The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.

Clinical Study Identifier: NCT04031885

Find a site near you

Start Over

Millennium Oncology

Hollywood, FL United States
  Connect »

Cleveland Clinic of Florida

Weston, FL United States
  Connect »